Aztreonam lysine (Cayston®) 75 mg powder and solvent for nebuliser solution
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013000420
English
Authors' recommendations:
Aztreonam lysine (Cayston®) is recommended as an option for restricted use within NHS Wales. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Aztreonam lysine (Cayston®) should be restricted for third-line use in the following subpopulation within its licensed indication for suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older:
• Patients in whom nebulised colistimethate sodium and nebulised tobramycin are not tolerated or are not providing satisfactory therapeutic benefit.
Aztreonam lysine (Cayston®) is not recommended for use within NHS Wales outside of this subpopulation.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/aztreonam%20lysine%20%28Cayston%29%201715%20FAR.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Administration, Inhalation
- Anti-Bacterial Agents
- Pharmaceutical Solutions
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.